GAVI and pneumococcal support

in page functions

Underlined label (for homepage use only) 

(Keep concise to take into account avoidance of line wrap when this spans over 1 column only) 

Highlight contents: 

GAVI support for pneumococcal vaccines

The GAVI Alliance has committed to support the introduction of pneumococcal vaccines in 19 developing countries from 2010 to 2012 and plans to roll them out to more than 40 countries by 2015, potentially averting more than 650,000 future deaths.

Image:  Kenya pneumococcal launchFeature image caption: 
Mary Wambui's daughter Esther receives the first of three pneumococcal vaccine doses, a scene to be repeated in health clinics across Kenya as it targets 85% pneumococcal vaccine coverage by 2012. Source: Riccardo Gangale/GAVI/2011.

Link Item

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

More facts...

close icon

modal window here